Avidity Biosciences, Inc. (RNAM)

Import this data to Google Sheets with:

=jivedata("RNAM","financials")

Full statements spill as a table. For one cell: =jivedata("RNAM","Revenue") or =jivedata("RNAM","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Avidity Biosciences, Inc.

RNAM • CIK 0001599901

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$9,560	$10,897	$18,755	$18,755
Operating Income (Loss)	$-235,598	$-378,936	$-745,943	$-745,943
Net Income (Loss) Attributable to Parent	$-212,220	$-322,302	$-684,631	$-684,631
Weighted Average Number of Shares Outstanding, Basic	73,012,000	111,582,000	137,710,000	137,710,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-209,397	$-319,525	$-684,971	$-684,971
Research and Development Expense	$190,968	$303,593	$559,159	$559,159
General and Administrative Expense	$54,190	$86,240	$205,539	$205,539
Operating Expenses	$245,158	$389,833	$764,698	$764,698
Investment Income, Nonoperating	$23,972	$56,882	$63,255	$63,255
Other Nonoperating Income (Expense)	$-594	$-248	$-1,943	$-1,943
Nonoperating Income (Expense)	$23,378	$56,634	$61,312	$61,312
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	$2,823	$2,777	$-451	$-451
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	—	—	$111	$111

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$185,082	$219,868	$382,517	$382,517
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	$410,269	$1,281,629	$1,314,352	$1,314,352
Property, Plant and Equipment, Net	$8,381	$12,670	$23,333	$23,333
Prepaid Expense and Other Assets, Current	$15,956	$40,793	$101,598	$101,598
Restricted Cash, Noncurrent	$295	$2,795	$2,797	$2,797
Assets, Current	$611,307	$1,542,290	$1,798,467	$1,798,467
Operating Lease, Right-of-Use Asset	$8,271	$5,619	$51,278	$51,278
Other Assets, Noncurrent	$301	$521	$82,175	$82,175
Assets	$628,555	$1,563,895	$1,958,050	$1,958,050
Operating Lease, Liability, Noncurrent	$6,213	$2,957	$45,313	$45,313
Contract with Customer, Liability, Noncurrent	$40,898	$37,961	$28,691	$28,691
Liabilities	$127,791	$138,936	$269,450	$269,450
Accounts Payable, Current	$8,809	$8,461	$12,403	$12,403
Accrued Liabilities and Other Liabilities	—	—	$157,466	$157,466
Operating Lease, Liability, Current	$3,639	$3,844	$3,938	$3,938
Contract with Customer, Liability, Current	$28,365	$20,987	$21,639	$21,639
Liabilities, Current	$80,680	$98,018	$195,446	$195,446
Common Stock, Value, Issued	$8	$12	$15	$15
Additional Paid in Capital, Common Stock	$1,071,395	$2,315,111	$3,263,720	$3,263,720
Accumulated Other Comprehensive Income (Loss), Net of Tax	$125	$2,902	$2,562	$2,562
Retained Earnings (Accumulated Deficit)	$-570,764	$-893,066	$-1,577,697	$-1,577,697
Stockholders' Equity Attributable to Parent	$500,764	$1,424,959	$1,688,600	$1,688,600
Common Stock, Shares Authorized	400,000,000	400,000,000	400,000,000	400,000,000
Common Stock, Shares, Issued	79,275,000	119,893,000	151,205,000	151,205,000
Operating Lease, Liability	$9,852	$6,801	$49,251	$49,251

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-212,220	$-322,302	$-684,631	$-684,631
Net Cash Provided by (Used in) Operating Activities	$-119,064	$-300,870	$-650,441	$-650,441
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	—	—	$137	$137
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-155,270	$37,286	$162,651	$162,651
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$185,377	$222,663	$385,314	$385,314
Depreciation	$2,101	$2,776	$4,151	$4,151
Payments to Acquire Debt Securities, Available-for-sale	$461,002	$1,433,535	$1,106,872	$1,106,872
Share-based Payment Arrangement, Noncash Expense	$38,222	$51,363	$97,838	$97,838
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	$335,160	$586,400	$1,086,222	$1,086,222
Accretion (Amortization) of Discounts and Premiums, Investments	$11,274	$21,447	$12,524	$12,524
Payments to Acquire Property, Plant, and Equipment	$4,228	$7,066	$13,319	$13,319
Gain (Loss) on Disposition of Property Plant Equipment	—	—	$-140	$-140
Payments for Leasing Costs, Commissions, and Tenant Improvements	—	—	$4,066	$4,066
Operating Lease, Right-of-Use Asset, Amortization Expense	$2,978	$3,297	$4,242	$4,242
Net Cash Provided by (Used in) Investing Activities	$-130,070	$-854,201	$-38,035	$-38,035
Increase (Decrease) in Prepaid Expense and Other Assets	$3,444	$25,057	$142,834	$142,834
Proceeds from Issuance of Common Stock	$60,547	$762,161	$836,882	$836,882
Increase (Decrease) in Accounts Payable	—	—	$3,799	$3,799
Proceeds from Issuance of Private Placement	$31,190	$238,388	$0	$0
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	—	—	$90,742	$90,742
Proceeds from Issuance of Warrants	—	$141,395	$0	$0
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	$2,127	$50,413	$26,517	$26,517
Increase (Decrease) in Contract with Customer, Liability	$62,987	$-10,315	$-8,618	$-8,618
Payment, Tax Withholding, Share-based Payment Arrangement	—	—	$12,409	$12,409
Net Cash Provided by (Used in) Financing Activities	$93,864	$1,192,357	$850,990	$850,990
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$1,741	$0	$45,195	$45,195
Capital Expenditures Incurred but Not yet Paid	—	$3,424	$1,634	$1,634

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("RNAM","financials")

Full statements spill as a table. For one cell: =jivedata("RNAM","Revenue") or =jivedata("RNAM","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.